Experimental drug duo targets Hard-to-Treat cancers

NCT ID NCT02142803

Ongoing Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 30, 2026 · Updated 2 times

Summary

This early-phase trial tests a new targeted drug called MLN0128 combined with bevacizumab (Avastin) in about 50 patients whose glioblastoma or other solid tumors have returned or not responded to standard treatment. The main goal is to find the safest dose and see how the body handles the combination. Researchers will also watch for any signs that the tumors stop growing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MLN0128 (a targeted drug) and bevacizumab (a monoclonal antibody)
What this could lead to: If it works, this could point toward a new treatment option for recurrent glioblastoma and other advanced solid tumors.
What could go wrong: This is a very early, small Phase 1 trial focused on safety and dosing, not proof of effectiveness. The combination may cause significant side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADULT GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adult glioblastoma endometrial clear cell adenocarcinoma endometrial serous adenocarcinoma fallopian tube neoplasm glioblastoma neoplasm ovarian cancer ovarian clear cell cystadenocarcinoma ovarian endometrioid adenocarcinoma ovarian mucinous cystadenocarcinoma ovarian serous cystadenocarcinoma uterine corpus cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADULT GLIOBLASTOMA ENDOMETRIAL CLEAR CELL ADENOCARCINOMA ENDOMETRIAL SEROUS ADENOCARCINOMA OVARIAN CLEAR CELL CYSTADENOCARCINOMA OVARIAN ENDOMETRIOID ADENOCARCINOMA OVARIAN MUCINOUS CYSTADENOCARCINOMA OVARIAN SEROUS CYSTADENOCARCINOMA RECURRENT FALLOPIAN TUBE CARCINOMA RECURRENT MALIGNANT UTERINE CORPUS NEOPLASM RECURRENT OVARIAN CARCINOMA RECURRENT PRIMARY PERITONEAL CARCINOMA SOLID NEOPLASM STAGE IIIA FALLOPIAN TUBE CANCER AJCC V7 STAGE IIIA OVARIAN CANCER AJCC V6 AND V7 STAGE IIIA PRIMARY PERITONEAL CANCER AJCC V7 STAGE IIIB FALLOPIAN TUBE CANCER AJCC V7 STAGE IIIB OVARIAN CANCER AJCC V6 AND V7 STAGE IIIB PRIMARY PERITONEAL CANCER AJCC V7 STAGE IIIC FALLOPIAN TUBE CANCER AJCC V7 STAGE IIIC OVARIAN CANCER AJCC V6 AND V7 STAGE IIIC PRIMARY PERITONEAL CANCER AJCC V7 STAGE IV FALLOPIAN TUBE CANCER AJCC V6 AND V7 STAGE IV OVARIAN CANCER AJCC V6 AND V7 STAGE IV PRIMARY PERITONEAL CANCER AJCC V7

Contacts and locations

Locations

Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Massachusetts General Hospital

Charlestown, Massachusetts, 02129, United States
Ohio State University Comprehensive Cancer Center

Columbus, Ohio, 43210, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.